BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32424876)

  • 1. PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: A clinicopathological study of 50 cases.
    Yamashita D; Shimada K; Kohno K; Kogure Y; Kataoka K; Takahara T; Suzuki Y; Satou A; Sakakibara A; Nakamura S; Asano N; Kato S
    Pathol Int; 2020 Aug; 70(8):513-522. PubMed ID: 32424876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
    Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
    Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
    Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
    Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.
    Miyoshi H; Kiyasu J; Kato T; Yoshida N; Shimono J; Yokoyama S; Taniguchi H; Sasaki Y; Kurita D; Kawamoto K; Kato K; Imaizumi Y; Seto M; Ohshima K
    Blood; 2016 Sep; 128(10):1374-81. PubMed ID: 27418641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced PD-L1 expression on tumor cells in primary CD30-positive cutaneous large T-cell lymphoma: a report of lymph node lesions of four cases.
    Takahashi E; Imai H; Tsuyuki Y; Taniguchi N; Kogure Y; Kataoka K; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Nakamura S
    J Clin Exp Hematop; 2023; 63(1):49-57. PubMed ID: 36990776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodal EBV+ cytotoxic T-cell lymphoma: A literature review based on the 2017 WHO classification.
    Kato S; Yamashita D; Nakamura S
    J Clin Exp Hematop; 2020; 60(2):30-36. PubMed ID: 32565530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.
    Mihashi Y; Kimura S; Iwasaki H; Oshiro Y; Takamatsu Y; Kawauchi S; Shimajiri S; Ishizuka K; Takeshita M
    Diagn Pathol; 2021 Nov; 16(1):101. PubMed ID: 34742294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features.
    Jeon YK; Kim JH; Sung JY; Han JH; Ko YH;
    Hum Pathol; 2015 Jul; 46(7):981-90. PubMed ID: 25907865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell receptor (TCR) phenotype of nodal Epstein-Barr virus (EBV)-positive cytotoxic T-cell lymphoma (CTL): a clinicopathologic study of 39 cases.
    Kato S; Asano N; Miyata-Takata T; Takata K; Elsayed AA; Satou A; Takahashi E; Kinoshita T; Nakamura S
    Am J Surg Pathol; 2015 Apr; 39(4):462-71. PubMed ID: 25634749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological analysis of neoplastic PD-L1-positive EBV
    Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
    Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nodal cytotoxic molecule (CM)-positive Epstein-Barr virus (EBV)-associated peripheral T cell lymphoma (PTCL): a clinicopathological study of 26 cases.
    Kato S; Takahashi E; Asano N; Tanaka T; Megahed N; Kinoshita T; Nakamura S
    Histopathology; 2012 Aug; 61(2):186-99. PubMed ID: 22690710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
    Takahashi E; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Tokura Y; Tamada Y; Nakamura S
    Pathol Int; 2020 Oct; 70(10):804-811. PubMed ID: 32783303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.
    Kawamoto K; Miyoshi H; Suzuki T; Kiyasu J; Yokoyama S; Sasaki Y; Sone H; Seto M; Takizawa J; Ohshima K
    Hematol Oncol; 2018 Aug; 36(3):591-599. PubMed ID: 29602174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FoxP3-positive T cell lymphoma arising in non-HTLV1 carrier: clinicopathological analysis of 11 cases of PTCL-NOS and 2 cases of mycosis fungoides.
    Satou A; Asano N; Kato S; Katsuya H; Ishitsuka K; Elsayed AA; Nakamura S
    Histopathology; 2016 Jun; 68(7):1099-108. PubMed ID: 26426838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
    Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
    Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
    Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
    Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reappraisal of nodal Epstein-Barr Virus-negative cytotoxic T-cell lymphoma: Identification of indolent CD5
    Yamashita D; Shimada K; Takata K; Miyata-Takata T; Kohno K; Satou A; Sakakibara A; Nakamura S; Asano N; Kato S
    Cancer Sci; 2018 Aug; 109(8):2599-2610. PubMed ID: 29845715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.